The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy
Open accessAbstract
BACKGROUND: Predicting survival is uniquely difficult in patients with pancreatic cancer who receive chemotherapy. The authors developed a systemic inflammation response index (SIRI) based on peripheral neutrophil, monocyte, and lymphocyte counts and evaluated the ability of the SIRI to predict the survival of patients with pancreatic cancer who received chemotherapy. METHODS: The SIRI was developed in a training set of 177 patients who had advanced pancreatic cancer and received palliative chemotherapy. The ability of the SIRI to predict a patient's survival after chemotherapy was validated in 2 independent cohorts (n = 397). RESULTS: Compared with patients who had an SIRI <1.8, patients in the training cohort who had an SIRI ≥1.8 had a shorter time to progression (TTP) (hazard ratio [HR], 2.348; 95% confidence interval, 1.559‐3.535; P = .003) and shorter overall survival (OS) (HR, 2.789; 95% confidence interval, 1.897‐4.121; P < .001). Comparable TTP and OS findings were observed in 2 independent validation cohorts. Multivariate analysis confirmed that the SIRI was an independent prognostic factor for both TTP and OS. In addition, compared with no change, an increase in the SIRI at week 8 was associated with poor TTP and OS, whereas a decrease in the SIRI was associated with improved outcomes. In addition, high SIRI scores were correlated with higher serum levels of interleukin 10, C‐C motif chemokine ligand 17 (CCL17), CCL18, and CCL22 and with a shortened TTP. CONCLUSIONS: The SIRI can be used to predict the survival of patients with pancreatic adenocarcinomas who receive chemotherapy, potentially allowing clinicians to improve treatment outcomes by identifying candidates for aggressive therapy. Cancer 2016;122:2158–67. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399 · cited 1×
“The hallmarks of cancer-related inflammation include the presence of inflammatory cells and inflammatory mediators (ie, chemokines, cytokines, etc) in tumor tissues.(23) A leukocyte infiltrate is present in most tumors.”
BackgroundFOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“The TAMs located in human tumors generally have an M2 phenotype, which is oriented toward promoting tumor growth, remodeling tissues, promoting angiogenesis, and suppressing adaptive immunity; the presence of these cells also alters responses to chemotherapeutic agents.(27,28) More specifically, proinflammatory, tumor…”
BackgroundCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“In the context of inflammation, neutrophil precursors, such as myelocytes and promyelocytes, might be released, thus leading to an increase in circulating granulocytes.(19) The prognostic and predictive usefulness of circulating neutrophils is apparent as an independent measure or as part of the NLR in many types of c…”
BackgroundCancer-related inflammation and treatment effectiveness
Diakos, C. I., Charles, K. A., McMillan, D. C., & Clarke, S. J. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70263-3 · Cited by 2,193
Cited by
Islam, M. M., Satici, M. O., & Eroglu, S. E. (2024) · Turkish Journal of Emergency Medicine · doi:10.4103/tjem.tjem_198_23 · Cited by 255
Prognostic value of the systemic inflammation response index in human malignancy: A meta-analysis
Wei, L., Xie, H., & Yan, P. (2020) · Medicine · doi:10.1097/md.0000000000023486 · Cited by 93
(2024) · doi:10.1038/s41598-024-70097-z · Cited by 58
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3499 · Cited by 42
“In this study we compared several immune and nutritional scores (NLR, PLR, LMR, ALI, SIRI, SII, PNI), extensively investigated in other cancers, including PDAC (24-27) and we documented the value of SII in prediction of patient outcome.”
Villegas García, L., Patró, E., Barbero, J. D., Esteve-Valverde, E., Palao, D. J., Soria, V., Labad, J., & Cobo, J. (2025) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107209 · Cited by 15
(2026) · doi:10.1007/s00213-026-07111-x
Metadata
- Authors
- Qi, Q., Zhuang, L., Shen, Y., Geng, Y., Yu, S., Chen, H., Liu, L., Meng, Z., Wang, P., & Chen, Z.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-05-06
- Volume
- 122
- Issue
- 14
- Pages
- 2158-2167
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2345885627
- Cited by
- 761
- References
- 33
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.